CONSOLIDATED BALANCE SHEETS (UNAUDITED) (USD $) In Millions, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Current Assets:
Cash and cash equivalents	$ 6,294	$ 5,571
Marketable Securities, Current	1,313	1,864
Receivables	3,458	3,390
Inventories	1,437	1,560
Deferred income taxes	1,885	1,644
Prepaid expenses and other	538	470
Assets held-for-sale, Current		109
Total Current Assets	14,925	14,608
Property, plant and equipment	4,323	4,417
Goodwill	7,027	7,027
Other intangible assets	1,706	1,753
Deferred income taxes	685	915
Marketable Securities, Noncurrent	4,279	4,408
Other assets	634	621
Total Assets	33,579	33,749
Current Liabilities:
Short-term borrowings	330	590
Accounts payable	2,346	2,487
Accrued expenses	1,791	2,459
Deferred income	1,459	1,167
Accrued rebates and returns	910	851
Income taxes payable	220	262
Dividends payable	633	645
Total Current Liabilities	7,689	8,461
Pension, postretirement and postemployment liabilities	1,156	1,115
Deferred income	697	770
Income taxes payable	638	560
Other liabilities	583	618
Long-term debt	7,127	7,242
Total Liabilities	17,890	18,766
Commitments and contingencies (Note 17)
Bristol-Myers Squibb Company Shareholders' Equity:
Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 4,191 in 2015 and 4,212 in 2014, liquidation value of $50 per share	0	0
Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.2 billion issued in both 2015 and 2014	221	221
Capital in excess of par value of stock	1,314	1,507
Accumulated other comprehensive loss	(2,416)	(2,425)
Retained earnings	33,110	32,541
Less cost of treasury stock - 541 million common shares in 2015 and 547 million in 2014	(16,683)	(16,992)
Total Bristol-Myers Squibb Company Shareholders' Equity	15,546	14,852
Noncontrolling interest	143	131
Total Equity	15,689	14,983
Total Liabilities and Equity	$ 33,579	$ 33,749